Shots:

• The longer-term analysis from the P-III trial evaluates the safety and efficacy of the COVID-19 vaccine in 2,228 individuals aged 12 through 15yrs. with COVID-19
• The results showed that a two-dose series of the COVID-19 Vaccine (30-µg/ dose) was 100% effective against COVID-19 was measured from 7 days through 4mos. after 2nd dose. The AEs were consistent with other clinical safety data for the vaccine & no serious safety concerns were observed @6mos. of safety follow-up after 2nd dose
• The companies will submit sBLA to the US FDA to expand approval of the vaccine for individuals aged 12yrs & also plan to submit data to seek regulatory approvals in other countries

Click here to­ read full press release | Ref: Pfizer | Image: Pfizer